Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Mar 28, 2014

NEW YORK (GenomeWeb News) – Stephen Rusckowski has been named chairman of the American Clinical Laboratory Association's board of directors.

Rusckowski has served as Quest Diagnostics' president and CEO since May 2012. Before joining Quest Diagnostics he was CEO of Philips Healthcare.

LabCorp said this week it has named Glenn Eisenberg to replace Brad Hayes as CFO. Eisenberg will take over the post officially when Hayes retires in June.

Eisenberg formerly was CFO and executive VP of finance and administration at Timken, and he held senior management posts at United Dominion Industries.

ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors.

Keegan was previously the CEO of ForteBio and Molecular Devices. Van Ingen was previously president of Agilent Technologies' bio-analytical measurement business. He currently serves on the boards of Bruker, Accelrys, and Promega.

Jay Wohlgemuth has been elected to the Personalized Medicine Coalition's board of directors. He is VP of science and innovation at Quest Diagnostics, and he formerly was director of clinical diagnostics at Genentech, VP of R&D at VIA Pharmaceuticals, and co-founder and chief medical officer at XDx.

Also at PMC, Amy Miller has been promoted to executive VP and will manage daily operations, while continuing to handle the duties of her previous position as VP of public policy. Phyllis Frosst has joined PMC as VP of science policy, as part of an effort to expand PMC's policy activities. Frosst previously was a research scientist and policy advisor at the National Institutes of Health.

Trovagene said this week that Charles Cantor has joined the company's scientific advisory board.

Cantor is currently adjunct professor of bioengineering at the University of California, San Diego; adjunct professor of molecular biology at the Scripps Research Institute; and distinguished adjunct professor of physiology and biophysics at the University of California, Irvine. He is also professor emeritus of biomedical engineering and pharmacology, and was the director of the Center for Advanced Biotechnology at Boston University. Cantor also is a founder and former CSO of Sequenom.

Agilent said this week that it has appointed Biogen Idec CEO George Scangos to its board of directors, effective in September.

Prior to Biogen, Scangos served as president and CEO of Exelixis, a drug discovery and development company. He was previously president of Bayer Biotechnology.

Pathway Genomics said this week that Kevin Davies has joined its scientific advisory board.

Davies is founding editor of Nature Genetics, a VP with the American Chemical Society, and is publisher of Chemical & Engineering News. He was the founding editor of Bio-IT World and an editor-in-chief at Cell Press.

Nikko Khazana has joined CompanionDx as senior VP of sales. He previously led the strategy and growth of Cardinal Health Specialty's group purchasing organization, and he led the build-out of Cardinal's urology division. He also previously was VP of corporate strategy and services with Supernova, a pharmaceutical marketing agency, VP and executive director of corporate accounts and new business development with the International Oncology Network, and director of US radiopharmaceutical operations with Mallinckrodt.

WaferGen Biosystems said this week during its 2013 earnings call that Maithreyan Srinivasan has joined the company as chief technology officer, and Nicolas Bardonnet has joined the firm as managing director for Europe.

Srinivasan is formerly a senior director of R&D at Agilent Technologies and director of molecular biology R&D at 454 Life Sciences/Roche Diagnostics. Bardonnet previously served as president of Qiagen France, and vice president of sales and marketing at Imagene.

Former Affymetrix CFO Tim Barabe has joined the board of directors of Opexa Therapeutics, a Woodlands, Texas-based biotechnology company.

Barabe retired from his role as CFO and executive vice president last year. Before joining the microarray vendor, he was also CFO of Human Genome Sciences and Regent Medical Ltd. Barabe also serves on the board of ArQule, a Boston-based biotech company, Opexa said.

Arno Therapeutics has appointed Randy Thurman vice chairman of its board of directors. Thurman, who joined Arno's board in January last year, was founder and CEO of VIASYS Healthcare, chairman and CEO of Corning Life Sciences, and chairman of Enzon. He also previously served as president of Rorer Pharmaceuticals and Rhone-Poulenc Rorer Pharmaceuticals.

Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.